Abstract
TableS1. Patient characteristics of the CHL study training cohorts. Table S2. Gene list for the targeted sequencing panel and HLGen. Table S3 Patient Demographic and molecular alterations. Table S4. HLGen correlation with Age and EBV in Training and Validation cohort. Table S5. Antibodies used for immunohistochemistry staining. Table S6. Differential gene expression analysis followed by gene ontology analysis in L-428 model. Table S7. Differential gene expression analysis followed by gene ontology analysis in U-HO1 model + IL-3. Table S8 Differential gene expression analysis followed by gene ontology analysis in U-HO1 model + IL-5. Table S9 Gene expression changes across all three experimental models. Table S10. Classification methods for HLGen. Table S11 HLGen Prediction in Training cohort. Table S12 HLGen Prediction in Stanford cohort (Alig and colleagues, Nature 2024). Table S13. Antibodies used for immunohistochemistry staining. Table S14. IMC Clustering Strategy. Table S15. Antibodies used for flow cytometry staining. Table S16. Antibodies used for Western blotting.